Navigation Links
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Date:11/1/2008

cluding HCV, HIV and tuberculosis."

About the Phase IIa Study

Investigators in five European countries assessed the antiviral activity, safety, and pharmacokinetics of two once-daily regimens of TMC435 (25 mg or 75 mg TMC435 versus placebo) in fifty HCV genotype 1 treatment-naive patients in an ongoing double-blind, placebo-controlled phase IIa trial. Patients were randomized to receive either seven days of monotherapy with TMC435 or placebo followed by 21 days of triple therapy with TMC435 or placebo, plus PegIFNalpha-2a (180 mcg once weekly) and RBV (1000-1200 mg daily); or, 28 days of triple therapy with TMC435 or placebo, plus PegIFNalpha-2a and RBV. After day 28, patients continue on PegIFNalpha-2a/RBV alone for a total of 24 or 48 weeks at the discretion of the investigator.

TMC435 data from other studies will also be presented at the AASLD Liver Meeting.

About HCV

According to the Centers for Disease Control and Prevention (CDC), about 3.2 million people in the United States are infected with chronic HCV and 19,000 people are newly infected each year.(4) Chronic infection with HCV can lead to cirrhosis and liver cancer, and is the most common cause of liver transplant in the United States.(4,5)

About Tibotec BVBA

Tibotec BVBA is a global pharmaceutical and research development company. The company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, Pa. and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need.

Forward Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could var
'/>"/>

SOURCE Tibotec BVBA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Many new dentists who are opening ... ensure that their practice will be a success. DentalDisposables.net is ... they use the most can make all the difference. Dentistry ... recently discovered that purchasing discount dental supplies can ... According to successful dentists across the United States ...
(Date:7/24/2014)... 2014  Kinex Pharmaceuticals announced the receipt of an ... Ointment for the commencement of a Phase I clinical ... IND to be allowed by the US FDA in ... synthetic, orally active and highly selective inhibitor of Src ... induction of p53, G2/M arrest of proliferating cell populations ...
(Date:7/24/2014)... 24, 2014 Research and Markets  has ... Market by Product, Component, Application and Geography - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to witness a moderate growth as the markets of ... almost reached the saturation levels. The demand is expected ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
... College of Emergency Physicians 2009 Scientific Assembly ... medical device company developing innovative portable and ... launch of its new palm-sized, affordable ultrasound ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091005/SF86741-a ) , (Logo: ...
... 5 Bausch & Lomb, the global eye health ... of Tubilux Pharma S.p.A. , Tubilux is a privately ... range of proprietary, over-the-counter, and branded generic products primarily ... countries. , Under the terms of the agreement, Bausch ...
Cached Medicine Technology:Signostics Introduces the World's Smallest Ultrasound Product for Global Demands of Affordable Healthcare 2Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 2
(Date:7/24/2014)... 24, 2014 Members of the Iowa State ... CCIM, Senior Associate of Sales at OutcomesMTM, as their Chairperson. ... to the Board and that his peers chose to keep ... provide the best I can for the citizens of Iowa,” ... positioned to provide a special insight to concerns and issues ...
(Date:7/24/2014)... new study has shown that it is possible to predict ... short-term effects of that same exposure. The findings, which currently ... it possible to develop simpler and cheaper tests to screen ... Despite an overall decrease in incidence of and mortality from ... the disease in their lifetime, and around 20 percent will ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... July 24, 2014 According to ... Business Models, Technology Roadmap, Forecasts and Analysis - ... is expected to reach $7.7 billion by 2018 ... , Browse 102 market data tables and 30 ... on “3D Mapping Market: Global Advancements, Business Models, ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... , , Congressman Chaka Fattah (D-PA) ... America,s healthcare system. , , WASHINGTON, Aug. 17 ... If real reform is to take place it must include a public ... airport in any major city they deliberate how they will get to their ...
... , , CHESTERFIELD, ... RELV ), a nutrition and direct selling company, today launched ... company,s line of proprietary nutritional supplements. , , ... Reliv,s breakthrough r(TM) skincare collection that combines some of the ...
... , , SAN FRANCISCO, ... leader in healthcare data management and decision support solutions ... a strategic alliance with CACTUS Software, a leading provider ... expand the capabilities and simplify the ability of healthcare ...
... , CHICAGO, Aug. 17 Presidential ... furnished two bedroom apartment to the University of Illinois Medical Center ... undergoing care at the medical center. , , ... Towers felt that this was a great way to give back ...
... PARK, N.J., Aug. 17 Managed Health Care Associates, Inc. ... joined MHA as Vice President & General Counsel. In ... all legal matters for the company, including healthcare compliance, contract ... and CFO of MHA commented "The establishment of this important ...
... Volumizing the Brow ... ... eyes change in generally predictable ways: the skin thins and becomes less elastic, brows may ... more prominent. While surgery has long been the accepted standard and offers significant benefits ...
Cached Medicine News:Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 2Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 3Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 2Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 3Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2Health News:MHA Announces Gloria Barr, Esq. as Vice President & General Counsel 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
... assayed control for immunophenotyping with Beckman Coulter® ... the accuracy and reproducibility of all the ... including red blood cell lysis. Reference values ... lymphocytes, B lymphocytes, granulocytes, monocytes, and NK ...
... storage and transport solution formulated ... cells in samples without reducing ... Samples treated with Cyto-Chex can ... seven days prior to analysis ...
... specially designed for use with Coulter® ... package includes diluent, lysing agent, cleaning ... The 15L package configuration includes diluent, ... card. The shelf life is one ...
Medicine Products: